Charleston (W.Va.) Area Medical Center, an affiliate of Vandalia Health, in collaboration with the CAMC Clinical Trials Center, is the first site in the world activated for the Bioflow-48 stent study ...

Overlapping of bioresorbable vascular scaffolds was linked to increased rates of periprocedural MI but no immediate or long-term effects on cardiac death, target lesion revascularization or stent ...

PHOENIX, AZ—In patients with diffuse CAD, a next-generation, longer-length stent may eliminate the need for multiple overlapping devices for treating long, continuous plaques, according to results ...

Please provide your email address to receive an email when new articles are posted on . A novel stent for treating long coronary lesions met its primary performance goal at 1 year. The 48-mm stent was ...

PHOENIX -- The novel, next-generation Xience drug-eluting stent (DES) with a 48-mm length met the performance bar with a particularly low restenosis rate, the SPIRIT 48 trial showed. The Xience ...

Few early differences exist among the various iterations of drug-eluting stents (DES). Instead, disparities between bioresorbable and permanent polymer devices only emerge over the long term, ...

BLOOMINGTON, Indiana — Following the advice of its advisory panel, the Food and Drug Administration has approved the Zilver PTX paclitaxel-eluting peripheral stent (Cook Medical, Bloomington, IN) for ...

Johnson & Johnson aims to seal a purchase of Guidant Corp. without immediately jettisoning the medical device maker's stent operations, sources familiar with the situation said on Thursday. A deal ...